Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-48d92e6f37b4f6c7f2463bf11b72f4f0"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-48d92e6f37b4f6c7f2463bf11b72f4f0"/>
<resource>
<Composition>
<id value="composition-en-48d92e6f37b4f6c7f2463bf11b72f4f0"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-48d92e6f37b4f6c7f2463bf11b72f4f0"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-48d92e6f37b4f6c7f2463bf11b72f4f0</b></p><a name="composition-en-48d92e6f37b4f6c7f2463bf11b72f4f0"> </a><a name="hccomposition-en-48d92e6f37b4f6c7f2463bf11b72f4f0"> </a><a name="composition-en-48d92e6f37b4f6c7f2463bf11b72f4f0-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1384/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - giapreza</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/19/1384/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp48d92e6f37b4f6c7f2463bf11b72f4f0"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - giapreza"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What GIAPREZA is and what it is used for</li><li>What you need to know before you are given GIAPREZA</li><li>How GIAPREZA is used</li><li>Possible side effects</li><li>How GIAPREZA is stored</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What giapreza is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What giapreza is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>GIAPREZA contains the active substance angiotensin II, a compound normally produced by the body. It makes the blood vessels tighten and become narrower, thus increasing blood pressure.</p><p>GIAPREZA is used in an emergency setting to increase blood pressure to normal levels in adult patients with seriously low blood pressure who do not respond to fluids or other medicines that raise blood pressure.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take giapreza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take giapreza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>You must not be given GIAPREZA:</p><ul><li>if you are allergic to angiotensin II or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Your doctor or nurse should be told if any of the above applies to you before this medicine is used.</p><p>Warnings and precautions<br/>GIAPREZA has only been tested in people with septic and distributive shock. It has not been tested in other types of shock.</p><p>Your doctor or nurse should be told before GIAPREZA is used if you or someone else in your family have a history of blood clots, as this medicine has been associated with the formation of blood clots. As a part of your treatment, you may be given medicine to prevent the formation of blood clots.</p><p>When you are first given GIAPREZA, it is expected that your blood pressure will increase. You will be monitored closely to make sure that your blood pressure is at the right level.</p><p>Tell your doctor or nurse immediately if you experience a change of colour (redness or paleness), pain, numbness in any of your limbs, or if any of your limbs are cold to the touch, as these could be signs that a blood clot has blocked blood flow to a part of the body.</p><p>Elderly GIAPREZA was tested in a small number of patients more than 75 years of age. There are no dose adjustments needed for patients more than 75 years of age. Your doctor will monitor your blood pressure and adjust your dose as needed.</p><p>Impairment of liver or kidneys There are no dose adjustments needed for patients with impairment of the function of the liver or kidneys. Your doctor will monitor your blood pressure and adjust your dose as needed.</p><p>Children and adolescents GIAPREZA should not be used in children or adolescents under 18 years of age as it has not been studied in these age groups.</p><p>Other medicines and GIAPREZA Your doctor should be told if you are using, have recently used, or might use any other medicines.</p><p>A number of medicines may affect the way GIAPREZA works, such as:</p><ul><li>Angiotensin converting enzyme (ACE) inhibitors (medicines used to lower blood pressure, with active substances whose name usually end in -pril). ACE inhibitors may increase to the effect of GIAPREZA.</li><li>Angiotensin II receptor blockers (medicines used to lower blood pressure, with active substances whose names usually end in -sartan) may lessen the effect of GIAPREZA.</li></ul><p>Your doctor may already be giving you other medicines used to increase your blood pressure. Adding GIAPREZA to these medicines may require that the doses of the other medicines be lowered.</p><p>Pregnancy, breast-feeding and fertility Your doctor should be told if you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby before this medicine is given.</p><p>There is limited information about the effects of GIAPREZA during pregnancy. Use of this medicine during pregnancy should be avoided if possible. You will only be given this medicine if the possible benefit is greater than the possible risks.</p><p>It is not known whether GIAPREZA can pass into breast milk. Your doctor should be told if you are breast-feeding before this medicine is given.</p><p>It is not known whether GIAPREZA can affect fertility.</p><p>Sodium This medicine contains less than 1 mmol sodium (23 mg) per 2.5 mg/1 ml, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take giapreza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take giapreza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>GIAPREZA will be given to you in a hospital by a doctor or a nurse. It is first diluted and then given as a drip (infusion) into a vein, supplying a specified dose each minute.</p><p>The dose depends on your body weight. The recommended starting rate of GIAPREZA is 20 nanograms (ng) per kilogram of your body weight per minute. After the initial dose, your doctor will adjust the rate as often as every 5 minutes until you achieve your target blood pressure. Your doctor will continue to assess your response and will adjust the dose accordingly up to a maximum of 80 ng per kilogram each minute during the first 3 hours of treatment. The maximum dose after the first 3 hours will be 40 ng per kilogram each minute.</p><p>GIAPREZA will be given to you at the lowest dose that helps you to achieve or maintain your blood pressure. In order to minimise the risk of side effects to this medicine, GIAPREZA will be withdrawn as soon as your condition improves.</p><p>If you are given more GIAPREZA than you should GIAPREZA will be given to you by a doctor or a nurse, so it is unlikely you will be given the wrong dose. However, if you have side effects or think you have been given too much GIAPREZA, tell your doctor or nurse straight away. If you have too much GIAPREZA, you may experience high blood pressure. If this occurs, hospital staff will monitor your vital signs and you will be provided with supportive care.</p><p>Stopping GIAPREZA treatment Your doctor will gradually decrease the amount of GIAPREZA you are given over time once your blood pressure has increased to appropriate levels. If GIAPREZA is stopped suddenly or stopped too early, you may experience a decrease in your blood pressure or your condition may worsen.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you experience:</p><ul><li>Pain, redness or pale colour, swelling or coolness to the touch of the skin or limbs, as these may be symptoms of a blood clot in one of your veins. These clots may travel through blood vessels to the lungs causing chest pain and difficulty breathing. If you notice any of these symptoms, seek medical advice immediately. These types of symptoms occur in greater than 1 out of every 10 patients. While not all of these symptoms lead to life-threatening complications, your doctor should be told about them immediately.</li></ul><p>Other side effects are: Very common side effects (may affect more than 1 in 10 people) are:</p><ul><li>Too high blood pressure</li></ul><p>Common side effects (may affect up to 1 in 10 people) are:</p><ul><li>Rapid heartbeat</li><li>Poor circulation to your hands, feet, or other bodily areas which can be severe and cause tissue damage.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store giapreza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store giapreza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP . The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C - 8 C). The diluted solution should be used immediately. Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature and 2 C - 8 C.</p><p>Do not use if you notice any signs of visible damage or discolouration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What GIAPREZA contains</p><ul><li>The active substance is angiotensin II acetate. Each ml contains angiotensin II acetate equivalent to 2.5 mg angiotensin II.</li><li>One vial of 1 ml concentrate for solution for infusion contains 2.5 mg of angiotensin II</li><li>One vial of 2 ml concentrate for solution for infusion contains 5 mg of angiotensin II</li><li>The other ingredients are mannitol and water for injections adjusted with sodium hydroxide and/or hydrochloric acid (see section 2 under Sodium ).</li></ul><p>What GIAPREZA looks like and contents of the pack GIAPREZA is presented as a concentrate for solution for infusion (sterile concentrate). The solution is a clear, colourless solution free of any visible particles.</p><p>GIAPREZA is supplied in a carton as a 1 x 1 ml, 10 x 1 ml or 1 x 2 ml single use vial. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder PAION Deutschland GmbH<br/>Heussstra e 52078 Aachen<br/>Germany</p><p>Manufacturer PAION Netherlands B.V. Vogt 6422 RK Heerlen Netherlands</p><p>PAION Deutschland GmbH Heussstra e 52078 Aachen Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Viatris bvba/sprl T l/Tel: + 32 (0)2 658 61 Lietuva<br/>PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4<br/>PAION Deutschland GmbH<br/>Te .: + 49 800 4453 4Luxembourg/Luxemburg<br/>PAION Deutschland GmbH<br/>T l/Tel: + 49 800 4453 4 esk republika PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4453<{e-mail}> Magyarorsz g<br/>PAION Deutschland GmbH<br/>Tel.: + 49 800 4453 4Danmark<br/>PAION Deutschland GmbH<br/>Tlf: + 49 800 4453 4Malta PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Deutschland PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Nederland PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Eesti PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Norge PAION Deutschland GmbH<br/>Tlf: + 49 800 4453 4<br/>Viatris Hellas Ltd : +30 210 0100 sterreich PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Espa a Viatris Pharmaceuticals, S.L.U. Tel: + 34 900 102 Polska Mylan Healthcare Sp. z o.o. Tel.: + 48 22 546 64 France Viatris Sant<br/>T l: +33 4 37 25 75 Portugal PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Hrvatska<br/>PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Rom nia BGP Products SRL Tel: +40 372 579 Ireland<br/>PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Slovenija PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4 sland PAION Deutschland GmbH<br/>S mi: + 49 800 4453 4Slovensk republika<br/>PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Italia Mylan Italia S.r.l. Tel: + 39 02 612 46Suomi/Finland PAION Deutschland GmbH<br/>Puh/Tel: + 49 800 4453 4<br/>PAION Deutschland GmbH<br/>: + 49 800 4453 4Sverige PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4Latvija<br/>PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4United Kingdom (Northern Ireland) PAION Deutschland GmbH<br/>Tel: + 49 800 4453 4This leaflet was last revised in MM/YYYY.</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp48d92e6f37b4f6c7f2463bf11b72f4f0"/>
<resource>
<MedicinalProductDefinition>
<id value="mp48d92e6f37b4f6c7f2463bf11b72f4f0"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp48d92e6f37b4f6c7f2463bf11b72f4f0"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp48d92e6f37b4f6c7f2463bf11b72f4f0</b></p><a name="mp48d92e6f37b4f6c7f2463bf11b72f4f0"> </a><a name="hcmp48d92e6f37b4f6c7f2463bf11b72f4f0"> </a><a name="mp48d92e6f37b4f6c7f2463bf11b72f4f0-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1384/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: GIAPREZA 2.5 mg/ml concentrate for solution for infusion</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/19/1384/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="GIAPREZA 2.5 mg/ml concentrate for solution for infusion"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
